Close Menu

NEW YORK (360Dx) – The US Food and Drug Administration recently cleared Beckman Coulter's ClearLLab reagents through the de novo process, giving laboratorians access, for the first time, to approved antibody cocktails that aid in the immunophenotyping and detection of certain leukemias and lymphomas.

The clearance of ClearLLab reagents, according to diagnostic industry experts, may have a noteworthy impact for clinicians testing for leukemias and lymphomas.  

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.